{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:43:14Z","timestamp":1790203394631,"version":"4.1.0"},"reference-count":138,"publisher":"Annual Reviews","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annu. Rev. Med."],"published-print":{"date-parts":[[2000,2]]},"abstract":"<jats:p>\u25aa Abstract\u2002 The amyloidoses are diseases in which abnormalities in the secondary structure of precursor proteins result in decreased solubility under physiologic conditions, with subsequent organ compromise. A total of 18 proteins have been definitively identified as amyloid precursors associated with human disease. Mutations in the genes that encode some of these proteins produce autosomal dominant disease in mid to late adult life. Until recently, the late onset has obscured the familial nature of some of the disorders. This is especially true in the apparently sporadic diseaseproducing deposits found even later in life. In many instances, these deposits are derived from precursors encoded by wild-type genes (perhaps influenced by alleles that are polymorphic in the normal population); in other cases, they represent autosomal dominant disease with age-dependent penetrance. The genetic aspects of amyloid diseases produced by the deposition of four different proteins have been investigated in detail and provide insights into the particular diseases and amyloidogenesis in general.<\/jats:p>","DOI":"10.1146\/annurev.med.51.1.543","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T11:45:04Z","timestamp":1027770304000},"page":"543-569","source":"Crossref","is-referenced-by-count":140,"title":["The Genetics of the Amyloidoses"],"prefix":"10.1146","volume":"51","author":[{"given":"Joel N.","family":"Buxbaum","sequence":"first","affiliation":[{"name":"Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, 92037, ;"},{"name":", Medical and Research Services, Department of Veterans Affairs, New York Harbor Healthcare System; Division of Rheumatology, Department of Medicine, New York University School of Medicine, New York, New York, 10010,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clement E.","family":"Tagoe","sequence":"additional","affiliation":[{"name":"Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, 92037, ;"},{"name":", Medical and Research Services, Department of Veterans Affairs, New York Harbor Healthcare System; Division of Rheumatology, Department of Medicine, New York University School of Medicine, New York, New York, 10010,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22","reference":[{"key":"b1","doi-asserted-by":"crossref","unstructured":"Chiti F, Webster P, Taddei N, et al. 1999. Designing conditions forin vitroformation of amyloid protofilaments and fibrils.Proc. Natl. Acad. Sci.USA96:3590\u201394","DOI":"10.1073\/pnas.96.7.3590"},{"key":"b2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.6.2375"},{"key":"b3","doi-asserted-by":"crossref","first-page":"6796","DOI":"10.1016\/S0021-9258(19)42128-5","volume":"249","year":"1974","journal-title":"J. Biol. Chem."},{"key":"b4","doi-asserted-by":"crossref","unstructured":"Blake CCF, Geisow MJ, Oatley SJ. 1978. Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8A.J. Mol. Biol.121:339\u201356","DOI":"10.1016\/0022-2836(78)90368-6"},{"key":"b5","doi-asserted-by":"crossref","unstructured":"Monaco HL, Rizzi M, Coda A. 1995. Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein.Science268:1039\u201341","DOI":"10.1126\/science.7754382"},{"key":"b6","first-page":"411","volume":"2","year":"1984","journal-title":"Mol. Biol. Med."},{"key":"b7","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(85)91956-4"},{"key":"b8","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/75.3.408"},{"key":"b9","first-page":"1","volume":"590","year":"1976","journal-title":"Acta Med. Scand. Suppl."},{"key":"b10","unstructured":"Sakoda S, Suzuki T, Higa S, et al. 1983. Genetic studies of familial amyloid polyneuropathy in the Arao district of Japan: 1. The genealogical survey.Clin. Genet.24:334\u201338"},{"key":"b11","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-86-4-419"},{"key":"b12","doi-asserted-by":"crossref","unstructured":"Saraiva MJM, Birken S, Costa PP, Goodman DS. 1984. Amyloid fibril protein in familial amyloidotic polyneuropathy, Portuguese type: definition of molecular abnormality in transthyretin (prealbumin).J. Clin. Invest.74:104\u201319","DOI":"10.1172\/JCI111390"},{"key":"b13","doi-asserted-by":"crossref","unstructured":"Tawara S, Nakazato M, Kangawa K, et al. 1983. Identification of amyloid prealbumin variant in familial amyloidotic polyneuropathy (Japanese type).Biochem. Biophys. Res. Commun.116:880\u2013 88","DOI":"10.1016\/S0006-291X(83)80224-1"},{"key":"b14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.81.3.694"},{"key":"b15","doi-asserted-by":"crossref","unstructured":"Jacobson DR, Santiago-Schwarz F, Buxbaum JN. 1988. Restriction fragment analysis confirms the position 33 mutation in transthyretin from an Israeli patient (SKO) with familial amyloidotic polyneuropathy.Biochem. Biophys. Res. Commun.153:198\u2013202","DOI":"10.1016\/S0006-291X(88)81208-7"},{"key":"b16","doi-asserted-by":"publisher","DOI":"10.1172\/JCI113293"},{"key":"b17","doi-asserted-by":"publisher","DOI":"10.1016\/0888-7543(89)90020-7"},{"key":"b18","unstructured":"1999.Proc. Int. Symp. Fam. Amyloidotic Polyneuropathy and Other Transthyretin Relat. Disord., 4th, Int. Workshop Liver Transplant. Fam. Amyloid Polyneuropathy, 3rd,June 3\u20135,Ume\u00e5, Sweden"},{"key":"b19","first-page":"308","volume":"95","year":"1995","journal-title":"Hum. Genet."},{"key":"b20","doi-asserted-by":"crossref","unstructured":"Kelly JW, Lansbury PT Jr. 1994. A chemical approach to elucidate the mechanism of transthyretin and beta-protein amyloid fibril formation.Amyloid:Int.J. Exp. Clin. Invest.1:186\u2013205","DOI":"10.3109\/13506129409148451"},{"key":"b21","doi-asserted-by":"crossref","unstructured":"Thylen C, Wahlqvist J, Haettner E, et al. 1993. Modifications of transthyretin in amyloid fibrils: analysis of amyloid from homozygous and heterozygous individuals with the Met30 mutation.EMBO J.12:743\u201348","DOI":"10.1002\/j.1460-2075.1993.tb05708.x"},{"key":"b22","doi-asserted-by":"crossref","unstructured":"McCutchen SL, Kelly J. 1993. Intermolecular disulfide linkages are not required for transthyretin amyloid fibril formationin vitro.Biochem. Biophys. Res. Commun.197:415\u201321","DOI":"10.1006\/bbrc.1993.2495"},{"key":"b23","doi-asserted-by":"crossref","unstructured":"McCutchen SL, Lai Z, Miroy GJ, et al. 1995. Comparison of lethal and nonlethal transthyretin variants and their relationship to disease.Biochemistry34:13527\u2013 36","DOI":"10.1021\/bi00041a032"},{"key":"b24","doi-asserted-by":"crossref","unstructured":"Coelho T, Sousa A, Lourenco E, Ramalheira J. 1994. A study of 159 Portuguese patients with familial amyloidotic polyneuropathy (FAP) whose parents were both unaffected.J. Med. Genet.31:293\u2013 99","DOI":"10.1136\/jmg.31.4.293"},{"key":"b25","unstructured":"Sousa A, Coelho T, Lobato L, Sequeiros J. 1999. Anticipation of age-at-onset in Portuguese patients with familial amyloid polyneuropathy-type I (FAPMet30). InAmyloidosis,ed. MA Gertz, RA Kyle. New York\/London: Parthenon. In press"},{"key":"b26","doi-asserted-by":"publisher","DOI":"10.1007\/s004390050991"},{"key":"b27","doi-asserted-by":"crossref","unstructured":"Sousa A, Coelho T, Sequeiros J. 1990. Parental transmission and age-of-onset in familial amyloidotic polyneuropathy (Portuguese type). InAmyloid and Amyloidosis,ed. JB Navtig, \u00d8 F\u00f8rre, G Husby, et al, pp. 691\u201393. Dordrecht, Netherlands\/Norwell, MA: Kluwer","DOI":"10.1007\/978-94-011-3284-8_170"},{"key":"b28","doi-asserted-by":"crossref","unstructured":"Ikegawa S, Yi S, Araki S, et al. 1990. Reevaluation of 134 patients with familial amyloidotic polyneuropathy (FAP) type I in Japan, Kumamoto focus. InAmyloid and Amyloidosis,ed. JB Navtig, \u00d8 F\u00f8rre, G Husby, et al, pp. 675\u201378. Dordrecht, Netherlands\/Norwell, MA: Kluwer","DOI":"10.1007\/978-94-011-3284-8_166"},{"key":"b29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0004.1988.tb02887.x"},{"key":"b30","doi-asserted-by":"publisher","DOI":"10.1007\/BF00288262"},{"key":"b31","doi-asserted-by":"crossref","unstructured":"Reilly MM, Adams D, Davis MB, et al. 1995. Haplotype analysis of French, British and other European patients with familial amyloid polyneuropathy (Met 30 and Tyr 77).J. Neurol.242:664\u201368","DOI":"10.1007\/BF00866917"},{"key":"b32","unstructured":"Ikeda S, Takei Y, Nakazato M, et al. 1999. Geographic distribution of familial amyloid polyneuropathy (FAP) in Japan. Proc. Int. Symp. Fam. Amyloidotic Polyneuropathy and Other Transthyretin Relat. Disord., 4th, Ume\u00e5, Sweden,P38:62"},{"key":"b33","doi-asserted-by":"crossref","unstructured":"Sousa A, Andersson R, Drugge U, et al. 1993. Familial amyloidotic polyneuropathy in Sweden: geographical distribution, age of onset, and prevalence.Hum. Hered.43:288\u201394","DOI":"10.1159\/000154146"},{"key":"b34","doi-asserted-by":"crossref","unstructured":"Holmgren G, Costa PM, Andersson C, et al. 1994. Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate.J. Med. Genet.31:351\u201354","DOI":"10.1136\/jmg.31.5.351"},{"key":"b35","doi-asserted-by":"crossref","unstructured":"Holmgren G, Ando Y, Wikstr\u00f6m L, et al. 1997. Discordant symptoms in monozygotic twins with familial amyloidotic polyneuropathy (FAP)(TTR Met 30).Amyloid: Int. J. Exp. Clin. Invest.4:178\u2013 80","DOI":"10.3109\/13506129709014382"},{"key":"b36","unstructured":"Soyka J. 1876. Ueber amyloide degeneration.Prag. Med. Wochenschr.9:165\u2013 71"},{"key":"b37","first-page":"362","volume":"44","year":"1908","journal-title":"Beitr. Pathol. Anat."},{"key":"b38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.7.2843"},{"key":"b39","doi-asserted-by":"crossref","unstructured":"Gorevic PD, Prelli FC, Wright J, et al. 1989. Systemic senile amyloidosis. Identification of a new prealbumin (transthyretin) variant in cardiac tissue: immunologic and biochemical similarity to one form of familial amyloidotic polyneuropathy.J. Clin. Invest.83:836\u201343","DOI":"10.1172\/JCI113966"},{"key":"b40","unstructured":"Jacobson DR, Gorevic PD, Buxbaum JN. 1990. A homozygous transthyretin variant associated with senile systemic amyloidosis: evidence for a late-onset disease of genetic etiology.Am. J. Hum. Genet.47:127\u201336"},{"key":"b41","unstructured":"Nichols WC, Liepnieks JJ, Snyder EL, Benson MD. 1991. Senile cardiac amyloidosis associated with homozygosity for a transthyretin variant (Ile-122).J. Lab. Clin. Med.117:175\u201380"},{"key":"b42","doi-asserted-by":"crossref","unstructured":"Saraiva MJM, Sherman W, Marboe C, et al. 1990. Cardiac amyloidosis: report of a patient heterozygous for the transthyretin-isoleucine 122 variant.Scand. J. Immunol.32:341\u201346","DOI":"10.1111\/j.1365-3083.1990.tb02928.x"},{"key":"b43","unstructured":"Snyder EC, Nichols WC, Liepnicks JJ, Benson MD. 1991. Direct evidence for hereditary nature of senile cardiac (systemic) amyloidosis.Am. J. Hum. Genet.45:A220 (Abstr.)"},{"key":"b44","doi-asserted-by":"publisher","DOI":"10.1007\/s004390050199"},{"key":"b45","unstructured":"Booth DR, Gillmore JD, Persey MR, et al. 1999. TTR mutations in patients with senile cardiac amyloidosis. InAmyloidosis,ed. MA Gertz, RA Kyle, pp. 554\u2013 55. New York, London: Parthenon"},{"key":"b46","doi-asserted-by":"crossref","unstructured":"Jacobson DR, Pastore RD, Yaghoubian R, et al. 1997. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans.N. Engl. J. Med.336:466\u201373","DOI":"10.1056\/NEJM199702133360703"},{"key":"b47","first-page":"1497","volume":"150","year":"1997","journal-title":"Am. J. Pathol."},{"key":"b48","unstructured":"Yamamura K. 1999. Development of mouse models for determination of factors involved in amyloidogenesis.Proc. Int. Symp. Fam. Amyloidotic Polyneuropathy Other Transthyretin Relat. Disord., 4th, Ume\u00e5, Sweden,S2:37"},{"key":"b49","unstructured":"Teng M, Yin J, Vidal R, et al. 1998. Age and sex-dependent amyloid fibril formation in mice transgenic for wild type human transthyretin.J. Invest. Med.46:192A (Abstr.)"},{"key":"b50","unstructured":"Buxbaum JN. 1997. The amyloidoses. InRheumatology,ed. JH Klippel, PA Dieppe, pp. 27.1\u201310. London: MosbyWolfe"},{"key":"b51","doi-asserted-by":"crossref","unstructured":"Sipe JD 1994. Amyloidosis.Crit. Rev. Clin. Lab. Sci.31:325\u201354","DOI":"10.3109\/10408369409084679"},{"key":"b52","unstructured":"Shiroo M, Kawahara E, Nakanishi I, Migita S. 1988. SAA2 deposition in the spleen of the mouse. InAmyloid and Amyloidosis,ed. T Isobe, S Araki, F Uchino, et al., pp. 63\u201368. London\/New York: Plenum"},{"key":"b53","doi-asserted-by":"publisher","DOI":"10.1084\/jem.148.4.1020"},{"key":"b54","doi-asserted-by":"crossref","unstructured":"Nomenclature Committee of the International Society of Amyloidosis. 1999. Revised nomenclature for serum amyloid A (SAA).Amyloid: Int. J. Exp. Clin. Invest.6:67\u201370","DOI":"10.3109\/13506129908993291"},{"key":"b55","doi-asserted-by":"crossref","unstructured":"Liepnieks JJ, Kluve-Beckerman B, Benson MD. 1995. Characterization of amyloid A protein in human secondary amyloidosis: the predominant deposition of serum amyloid A1.Biochim. Biophys. Acta1270:81\u201386","DOI":"10.1016\/0925-4439(94)00076-3"},{"key":"b56","doi-asserted-by":"crossref","unstructured":"Booth DR, Booth SE, Gillmore JD, et al. 1998. SAA1 alleles as risk factors in reactive systemic AA amyloidosis.Amyloid: Int. J. Exp. Clin. Invest.5:262\u201365","DOI":"10.3109\/13506129809007299"},{"key":"b57","doi-asserted-by":"crossref","unstructured":"Faulkes DJ, Woo P. 1997. Do alleles at the serum amyloid A locus influence susceptibility to reactive amyloidosis in systemic onset juvenile chronic arthritis?Amyloid: Int. J. Exp. Clin. Invest.4:75\u2013 79","DOI":"10.3109\/13506129708995274"},{"key":"b58","doi-asserted-by":"crossref","unstructured":"Yamada T, Okuda Y, Itoh Y. 1998. The frequency of serum amyloid A2 alleles in the Japanese population.Amyloid: Int. J. Exp. Clin. Invest.5:208\u201311","DOI":"10.3109\/13506129809003847"},{"key":"b59","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199807000-00005"},{"key":"b60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198604173141601"},{"key":"b61","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197410312911803"},{"key":"b62","doi-asserted-by":"publisher","DOI":"10.1038\/ng0997-25"},{"key":"b63","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80539-5"},{"key":"b64","doi-asserted-by":"crossref","unstructured":"Livneh A, Langevitz P, Shinar Y, et al. 1999. MEFV mutation analysis in patients suffering from amyloidosis of familial Mediterranean fever.Amyloid: Int. J. Exp. Clin. Invest.6:1\u20136","DOI":"10.3109\/13506129908993281"},{"key":"b65","doi-asserted-by":"crossref","unstructured":"Kindy MS, deBeer FC, Markesbery WR, et al. 1995. Apolipoprotein E genotypes in AA and AL amyloidoses.Amyloid: Int. J. Exp. Clin. Invest.2:159\u201362","DOI":"10.3109\/13506129509036919"},{"key":"b66","doi-asserted-by":"crossref","unstructured":"Evans DA, Funkenstein HH, Albert MS, et al. 1989. Prevalence of Alzheimer\u2019s disease in a community population of older persons. Higher than previously reported.J. Am. Med. Assoc.262:2551\u2013 56","DOI":"10.1001\/jama.1989.03430180093036"},{"key":"b67","doi-asserted-by":"crossref","unstructured":"Glenner GG, Wong CW. 1984. Alzheimer\u2019s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein.Biochem. Biophys. Res. Commun.120:885\u2013 90","DOI":"10.1016\/S0006-291X(84)80190-4"},{"key":"b68","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.10.4748"},{"key":"b69","doi-asserted-by":"crossref","unstructured":"Schlossmacher MG, Ostaszewski BL, Hecker LI, et al. 1992. Detection of distinct isoform patterns of the beta-amyloid precursor protein in human platelets and lymphocytes.Neurobiol. Aging13:421\u2013 34","DOI":"10.1016\/0197-4580(92)90117-G"},{"key":"b70","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(95)90073-X"},{"key":"b71","doi-asserted-by":"publisher","DOI":"10.1038\/325733a0"},{"key":"b72","doi-asserted-by":"crossref","unstructured":"Sandbrink R, Masters CL, Beyreuther K. 1996. APP gene family. Alternative splicing generates functionally related isoforms.Ann. NY Acad. Sci.777:281\u2013 87","DOI":"10.1111\/j.1749-6632.1996.tb34433.x"},{"key":"b73","doi-asserted-by":"publisher","DOI":"10.1038\/19083"},{"key":"b74","doi-asserted-by":"crossref","unstructured":"Iwatsubo T, Odaka A, Suzuki N, et al. 1994. Visualization of A beta 42(43)positive and A beta 40-positive senile plaques with end-specific A beta-monoclonal antibodies: evidence that an initially deposited A beta species is A beta 1\u201342(43).Neuron13:45\u201353","DOI":"10.1016\/0896-6273(94)90458-8"},{"key":"b75","doi-asserted-by":"publisher","DOI":"10.1038\/360672a0"},{"key":"b76","doi-asserted-by":"publisher","DOI":"10.1038\/375754a0"},{"key":"b77","doi-asserted-by":"publisher","DOI":"10.1126\/science.7638622"},{"key":"b78","doi-asserted-by":"crossref","unstructured":"Suzuki N, Cheung TT, Cai XD, et al. 1994. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants.Science264:1336\u201340","DOI":"10.1126\/science.8191290"},{"key":"b79","doi-asserted-by":"crossref","unstructured":"Armstrong RA. 1994. Differences in beta-amyloid (beta\/A4) deposition in human patients with Down\u2019s syndrome and sporadic Alzheimer\u2019s disease.Neurosci. Lett.169:133\u201336","DOI":"10.1016\/0304-3940(94)90374-3"},{"key":"b80","doi-asserted-by":"publisher","DOI":"10.1038\/ng0195-21"},{"key":"b81","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1996.tb34436.x"},{"key":"b82","doi-asserted-by":"crossref","unstructured":"Blacker D, Tanzi RE. 1998. The genetics of Alzheimer disease: current status and future prospects.Arch. Neurol.55:294\u2013 96","DOI":"10.1001\/archneur.55.3.294"},{"key":"b83","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410400619"},{"key":"b84","doi-asserted-by":"publisher","DOI":"10.1038\/349704a0"},{"key":"b85","doi-asserted-by":"crossref","unstructured":"Wisniewski T, Frangione B 1992. Molecular biology of Alzheimer\u2019s amyloid\u2013Dutch variant.Mol. Neurobiol.6:75\u201386","DOI":"10.1007\/BF02935567"},{"key":"b86","doi-asserted-by":"crossref","unstructured":"Mullan M, Crawford F, Axelman K, et al. 1992. A pathogenic mutation for probable Alzheimer\u2019s disease in the APP gene at theN-terminus of beta-amyloid. Nature Genet.1:345\u201347","DOI":"10.1038\/ng0892-345"},{"key":"b87","doi-asserted-by":"publisher","DOI":"10.1126\/science.2111584"},{"key":"b88","doi-asserted-by":"publisher","DOI":"10.1126\/science.1411576"},{"key":"b89","doi-asserted-by":"crossref","unstructured":"Tomita T, Maruyama K, Saido TC, et al. 1997. The presenilin-2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid beta protein ending at the 42nd (or 43rd) residue.Proc. Natl. Acad. Sci. USA94:2025\u201330","DOI":"10.1073\/pnas.94.5.2025"},{"key":"b90","doi-asserted-by":"publisher","DOI":"10.1038\/19077"},{"key":"b91","doi-asserted-by":"publisher","DOI":"10.1038\/34910"},{"key":"b92","doi-asserted-by":"crossref","unstructured":"Levitan D, Greenwald I. 1995. Facilitation of lin-12-mediated signalling by sel12, aCaenorhabditis elegansS182 Alzheimer\u2019s disease gene.Nature377:351\u201354","DOI":"10.1038\/377351a0"},{"key":"b93","doi-asserted-by":"crossref","unstructured":"Baumeister R, Leimer U, Zweckbronner I, et al. 1997. Human presenilin 1, but not familial Alzheimer\u2019s disease (FAD) mutants, facilitateCaenorhabditis elegansNotch signaling independently of proteolytic processing.Genes Funct.1:149\u201359","DOI":"10.1046\/j.1365-4624.1997.00012.x"},{"key":"b94","doi-asserted-by":"publisher","DOI":"10.1038\/5526"},{"key":"b95","doi-asserted-by":"crossref","unstructured":"Weidemann A, Paliga K, Durrwang U, et al. 1997. Formation of stable complexes between two Alzheimer\u2019s diseases gene products: presenilin-2 and beta-amyloid precursor protein.Nature Med.3:328\u201332","DOI":"10.1038\/nm0397-328"},{"key":"b96","doi-asserted-by":"publisher","DOI":"10.1038\/376775a0"},{"key":"b97","doi-asserted-by":"publisher","DOI":"10.1038\/373523a0"},{"key":"b98","doi-asserted-by":"publisher","DOI":"10.1126\/science.274.5284.99"},{"key":"b99","doi-asserted-by":"publisher","DOI":"10.1038\/nm0198-097"},{"key":"b100","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.24.13287"},{"key":"b101","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.15.5810"},{"key":"b102","doi-asserted-by":"publisher","DOI":"10.1038\/341162a0"},{"key":"b103","first-page":"526","volume":"145","year":"1994","journal-title":"Am. J. Pathol."},{"key":"b104","doi-asserted-by":"crossref","first-page":"22358","DOI":"10.1016\/S0021-9258(17)31797-0","volume":"269","year":"1994","journal-title":"J. Biol. Chem."},{"key":"b105","doi-asserted-by":"crossref","unstructured":"Franceschini G. 1996. Apolipoprotein function in health and disease: insights from natural mutations.Eur. J. Clin. Invest.26:733\u201346","DOI":"10.1046\/j.1365-2362.1996.2120536.x"},{"key":"b106","first-page":"49","volume":"7","year":"1989","journal-title":"Dis. Markers"},{"key":"b107","doi-asserted-by":"publisher","DOI":"10.1038\/ng0194-29"},{"key":"b108","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)93288-X"},{"key":"b109","doi-asserted-by":"crossref","unstructured":"Gejyo F, Suzuki S, Kimura H, et al. 1997. Increased risk of dialysis-related amyloidosis in patients with the apolipoprotein E4 allele.Amyloid: Int. J. Exp. Clin. Invest.4:13\u201317","DOI":"10.3109\/13506129708995263"},{"key":"b110","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.8.1467"},{"key":"b111","doi-asserted-by":"publisher","DOI":"10.1038\/ng0694-180"},{"key":"b112","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199511093331902"},{"key":"b113","doi-asserted-by":"crossref","unstructured":"Blacker D, Haines JL, Rodes L, et al. 1997. Apo E-4 and age at onset of Alzheimer\u2019s disease: the NIMH genetics initiative.Neurology48:139\u201347","DOI":"10.1212\/WNL.48.1.139"},{"key":"b114","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410380120"},{"key":"b115","unstructured":"Wisniewski T, Castano EM, Golabek AA, et al. 1994. Acceleration of Alzheimer\u2019s fibril formation by apolipoprotein Ein vitro.Am. J. Pathol.145:1030\u201335"},{"key":"b116","doi-asserted-by":"publisher","DOI":"10.1038\/ng1197-263"},{"key":"b117","doi-asserted-by":"crossref","unstructured":"Maestre G, Ottman R, Stern Y, et al. 1995. Apolipoprotein E and Alzheimer\u2019s disease: ethnic variation in genotypic risks.Ann. Neurol.37:254\u201359","DOI":"10.1002\/ana.410370217"},{"key":"b118","unstructured":"Mayeux R, Saunders AM, Shea S, et al. 1998. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer\u2019s disease. Alzheimer\u2019s disease centers consortium in apolipoprotein E and Alzheimer\u2019s disease.N. Engl. J. Med.338:506\u2013 11"},{"key":"b119","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1997.69051904.x"},{"key":"b120","doi-asserted-by":"publisher","DOI":"10.1038\/1243"},{"key":"b121","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.6.3275"},{"key":"b122","doi-asserted-by":"crossref","unstructured":"Liao A, Nitsch RM, Greenberg SM, et al. 1998. Genetic association of an alpha 2macroglobulin (Val1000Ile) polymorphism and Alzheimer\u2019s disease.Hum. Mol. Genet.7:1953\u201356","DOI":"10.1093\/hmg\/7.12.1953"},{"key":"b123","doi-asserted-by":"crossref","unstructured":"Castillo GM, Ngo C, Cummings J, et al. 1997. Perlecan binds to the beta-amyloid proteins (A beta) of Alzheimer\u2019s disease, accelerates A beta fibril formation, and maintains A beta fibril stability.J. Neurochem.69:2452\u201365","DOI":"10.1046\/j.1471-4159.1997.69062452.x"},{"key":"b124","doi-asserted-by":"publisher","DOI":"10.1126\/science.279.5348.242"},{"key":"b125","doi-asserted-by":"publisher","DOI":"10.1159\/000137173"},{"key":"b126","first-page":"149","volume":"87","year":"1994","journal-title":"Q.J. Med."},{"key":"b127","first-page":"1186","volume":"147","year":"1995","journal-title":"Am. J. Pathol."},{"key":"b128","doi-asserted-by":"crossref","unstructured":"Sorci-Thomas M, Kearns MW, Lee JP, et al. 1993. Apolipoprotein A-I domains involved in lecithin-cholesterol acyltransferase activation. Structure:function relationships.J. Biol. Chem.268:21403\u20139","DOI":"10.1016\/S0021-9258(19)36938-8"},{"key":"b129","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1997.8005"},{"key":"b130","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0022-2275(20)41439-7","volume":"33","year":"1992","journal-title":"J. Lipid Res."},{"key":"b131","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.16.7389"},{"key":"b132","first-page":"695","volume":"88","year":"1995","journal-title":"Q.J. Med."},{"key":"b133","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118725"},{"key":"b134","doi-asserted-by":"crossref","unstructured":"Persey MR, Booth DR, Booth SE, et al. 1998. Hereditary nephropathic systemic amyloidosis caused by a novel variant apolipoprotein A-1.Kidney Int.53:276\u2013 81","DOI":"10.1046\/j.1523-1755.1998.00770.x"},{"key":"b135","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1999.0518"},{"key":"b136","doi-asserted-by":"crossref","unstructured":"Hamidi Asl L, Liepnicks JJ, Hamidi Asl K, et al. 1999. Hereditary amyloid cardiomyopathy caused by a variant apolipoprotein A1.Am. J. Pathol.154:221\u2013 27","DOI":"10.1016\/S0002-9440(10)65268-6"},{"key":"b137","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.46.1.57"},{"key":"b138","doi-asserted-by":"crossref","unstructured":"Westermark P, Araki S, Benson MD, et al. 1999. Part 1. Nomenclature of amyloid fibril proteins.Amyloid: Int. J. Exp. Clin. Invest.6:63\u201366","DOI":"10.3109\/13506129908993290"}],"container-title":["Annual Review of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.annualreviews.org\/doi\/pdf\/10.1146\/annurev.med.51.1.543","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,23]],"date-time":"2023-04-23T18:59:05Z","timestamp":1682276345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.annualreviews.org\/doi\/10.1146\/annurev.med.51.1.543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,2]]},"references-count":138,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2000,2]]}},"alternative-id":["10.1146\/annurev.med.51.1.543"],"URL":"https:\/\/doi.org\/10.1146\/annurev.med.51.1.543","relation":{},"ISSN":["0066-4219","1545-326X"],"issn-type":[{"value":"0066-4219","type":"print"},{"value":"1545-326X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,2]]}}}